Maxim Group analyst Jason McCarthy maintained a Buy rating on MetaVia yesterday and set a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors related to MetaVia’s promising developments in their obesity drug candidate, DA-1726. The company has shown progress in their clinical trials, specifically with the extension of the multiple ascending doses study to 8 weeks, which aims to further evaluate the drug’s efficacy and safety. The initial results have indicated a favorable trend in weight loss without significant cardiovascular risks, which enhances the drug’s potential in the market.
Additionally, MetaVia’s strategic collaboration with Syntekbio for AI-driven exploration of DA-1726 further strengthens their research capabilities. The valuation model considers a 70% revenue risk adjustment for DA-1726 and an 80% adjustment for DA-1241, with a 30% discount rate applied to derive a 12-month price target of $6.00. These factors collectively contribute to McCarthy’s optimistic outlook and Buy rating for MetaVia’s stock.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MTVA in relation to earlier this year.